Loading…
Camp4 Therapeutics Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -63.1% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $6.13 | $5.22 | |
| P/S | — | 91.0x | 161.4x |
| P/B | — | 6.7x | 1.7x |
| EPS | -$2.65 | -$11.04 | |
| Profit margin | — | -2298.54% | -7943.40% |
| ROE | — | -168.55% | -82.02% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NAGENiagen Bioscience, Inc. | $3.29 | 17.3x | 3.2x | — | 21.80% | $260.32M |
| ELDNEledon Pharmaceuticals, Inc. | $3.20 | — | 3.6x | — | -110.71% | $260.04M |
| STROSutro Biopharma Inc | $15.73 | — | — | — | — | $260.82M |
| INFUInfuSystem Holdings, Inc | $13.11 |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company description provided by Yahoo Finance.
| 32.8x |
| 4.4x |
| — |
| 15.03% |
| $261.11M |
| AKBAAkebia Therapeutics, Inc. | $0.93 | — | 10.1x | — | -109.38% | $258.43M |
| WHWKWhitehawk Therapeutics, Inc. | $4.62 | — | 1.9x | — | -44.98% | $263.38M |